Skip to main content

Table 2 Any treatment received and time to treatment (Commercial and Medicaid populations; 12-month follow-up, by age)

From: Contemporary treatment utilization among women diagnosed with symptomatic uterine fibroids in the United States

 

Age category

18–24 years

25–29 years

30–34 years

35–39 years

40–44 years

45–49 years

50–54 years

55–59 years

60–64 years

Commercial population (n = 225,737)

n

1532

5485

19,562

40,403

62,861

58,717

25,741

7494

3942

 Any treatment, n (%)

1114 (72.7)

4161 (75.9)

14,307 (73.1)

29,570 (73.2)

45,557 (72.5)

40,144 (68.4)

14,788 (57.4)

3220 (43.0)

1505 (38.2)

 Mean (SD) time to first treatmenta, days

57.0 (82.4)

63.6 (87.2)

62.5 (88.4)

57.3 (83.1)

53.1 (78.3)

53.8 (78.7)

58.7 (84.5)

76.7 (96.9)

76.4 (97.4)

  Pharmacologic treatment

61.9 (85.5)

72.1 (92.2)

76.7 (96.5)

76.1 (94.7)

72.8 (91.4)

76.1 (93.7)

90.1 (101.1)

117.1 (107.6)

116.9 (107.4)

  Surgical treatment

30.1 (55.8)

42.2 (68.6)

39.3 (67.1)

37.9 (63.5)

38.5 (63.2)

39.1 (62.9)

37.1 (62.2)

35.3 (61.5)

26.7 (49.9)

 Mean (SD) time to second treatment, days

129.8 (102.2)

129.4 (108.4)

117.6 (105.2)

106.2 (102.3)

99.7 (99.2)

95.0 (97.2)

92.5 (97.9)

82.5 (94.6)

90.3 (98.7)

 Pharmacologicb, n (%)

  Any

1052 (68.7)

3745 (68.3)

12,156 (62.1)

23,047 (57.0)

33,028 (52.5)

27,850 (47.4)

10,096 (39.2)

2362 (31.5)

1121 (28.4)

  Aromatase inhibitor

5 (0.3)

98 (1.8)

311 (1.6)

391 (1.0)

226 (0.4)

29 (< 0.1)

4 (< 0.1)

2 (< 0.1)

0 (0.0)

  Danazol

1 (0.1)

0 (0.0)

15 (0.1)

11 (< 0.1)

23 (< 0.1)

11 (< 0.1)

4 (< 0.1)

1 (< 0.1)

0 (0.0)

  Dopamine promoter

2 (0.1)

20 (0.4)

117 (0.6)

146 (0.4)

118 (0.2)

76 (0.1)

24 (0.1)

6 (0.1)

0 (0.0)

  GnRH agonist

45 (2.9)

185 (3.4)

617 (3.2)

929 (2.3)

1048 (1.7)

780 (1.3)

263 (1.0)

13 (0.2)

0 (0.0)

  Hormonal contraceptivec

829 (54.1)

2351 (42.9)

6187 (31.6)

9206 (22.8)

10,290 (16.4)

6840 (11.6)

1583 (6.1)

70 (0.9)

8 (0.2)

  Iron supplement

49 (3.2)

330 (6.0)

1002 (5.1)

1249 (3.1)

816 (1.3)

286 (0.5)

71 (0.3)

8 (0.1)

3 (0.1)

  NSAID

493 (32.2)

2189 (39.9)

7714 (39.4)

16,310 (40.4)

25,289 (40.2)

22,482 (38.3)

8656 (33.6)

2243 (29.9)

1065 (27.0)

  SERM

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

9 (< 0.1)

12 (< 0.1)

33 (0.1)

54 (0.7)

65 (1.6)

  Tranexamic acid

13 (0.8)

66 (1.2)

261 (1.3)

610 (1.5)

1010 (1.6)

939 (1.6)

331 (1.3)

17 (0.2)

0 (0.0)

 Surgicalb, n (%)

  Any

254 (16.6)

1695 (30.9)

7399 (37.8)

18,524 (45.8)

32,251 (51.3)

29,177 (49.7)

10,175 (39.5)

1740 (23.2)

724 (18.4)

  Ablation

15 (1.0)

114 (2.1)

650 (3.3)

2355 (5.8)

4932 (7.8)

4915 (8.4)

1477 (5.7)

94 (1.3)

17 (0.4)

  Hysterectomy

23 (1.5)

366 (6.7)

2874 (14.7)

10,723 (26.5)

22,661 (36.0)

21,570 (36.7)

7822 (30.4)

1500 (20.0)

627 (15.9)

  Myomectomy

219 (14.3)

1248 (22.8)

3908 (20.0)

5555 (13.7)

4703 (7.5)

2715 (4.6)

950 (3.7)

152 (2.0)

81 (2.1)

  Myomectomy and ablation

5 (0.3)

30 (0.5)

120 (0.6)

371 (0.9)

722 (1.1)

767 (1.3)

217 (0.8)

20 (0.3)

4 (0.1)

  Uterine artery embolization

4 (0.3)

18 (0.3)

177 (0.9)

577 (1.4)

1244 (2.0)

1243 (2.1)

326 (1.3)

37 (0.5)

4 (0.1)

Medicaid population (n = 19,062)

n

593

1631

3385

4583

4340

2976

1017

379

158

 Any treatment, n (%)

468 (78.9)

1380 (84.6)

2860 (84.5)

3828 (83.5)

3589 (82.7)

2389 (80.3)

728 (71.6)

234 (61.7)

98 (62.0)

 Mean (SD) time to first treatmenta, days

66.4 (87.1)

58.7 (86.8)

53.7 (80.4)

51.5 (76.5)

52.0 (76.2)

57.0 (80.9)

58.1 (82.8)

71.0 (82.1)

86.4 (98.6)

  Pharmacologic treatment

70.9 (89.1)

70.0 (93.8)

65.2 (88.8)

64.1 (85.5)

64.6 (85.7)

66.1 (86.5)

69.7 (91.6)

82.1 (87.3)

109.4 (104.6)

  Surgical treatment

23.5 (46.5)

23.9 (45.3)

29.8 (51.8)

31.6 (53.7)

33.1 (53.9)

42.5 (68.4)

37.0 (58.4)

35.7 (48.8)

31.6 (51.6)

 Mean (SD) time to second treatment, days

143.0 (109.9)

119.5 (102.7)

111.1 (102.7)

99.0 (96.5)

98.1 (96.8)

101.9 (98.8)

97.8 (97.3)

99.0 (104.6)

106.9 (85.7)

 Pharmacologicb, n (%)

  Any

459 (77.4)

1307 (80.1)

2622 (77.5)

3459 (75.5)

3196 (73.6)

2127 (71.5)

640 (62.9)

218 (57.5)

89 (56.3)

  Aromatase inhibitor

1 (0.2)

1 (0.1)

3 (0.1)

4 (0.1)

5 (0.1)

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

  Danazol

0 (0.0)

1 (0.1)

3 (0.1)

2 (< 0.1)

1 (< 0.1)

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

  Dopamine promoter

0 (0.0)

1 (< 0.1)

3 (0.1)

2 (< 0.1)

8 (0.2)

1 (< 0.1)

0 (0.0)

1 (0.3)

0 (0.0)

  GnRH agonist

18 (3.0)

41 (2.5)

71 (2.1)

88 (1.9)

74 (1.7)

54 (1.8)

8 (0.8)

2 (0.5)

0 (0.0)

  Hormonal contraceptivec

258 (43.5)

573 (35.1)

819 (24.2)

826 (18.0)

532 (12.3)

252 (8.5)

28 (2.8)

4 (1.1)

0 (0.0)

  Iron supplement

111 (18.7)

261 (16.0)

508 (15.0)

762 (16.6)

719 (16.6)

489 (16.4)

141 (13.9)

20 (5.3)

3 (1.9)

  NSAID

349 (58.9)

1035 (63.5)

2191 (64.7)

2961 (64.6)

2756 (63.5)

1882 (63.2)

573 (56.3)

205 (54.1)

87 (55.1)

  SERM

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

1 (< 0.1)

4 (0.4)

0 (0.0)

1 (0.6)

  Tranexamic acid

1 (0.2)

11 (0.7)

37 (1.1)

40 (0.9)

46 (1.1)

21 (0.7)

2 (0.2)

0 (0.0)

0 (0.0)

 Surgicalb, n (%)

  Any

65 (11.0)

465 (28.5)

1308 (38.6)

2071 (45.2)

2060 (47.5)

1282 (43.1)

328 (32.3)

69 (18.2)

32 (20.3)

  Ablation

15 (2.5)

70 (4.3)

212 (6.3)

344 (7.5)

366 (8.4)

194 (6.5)

30 (2.9)

3 (0.8)

0 (0.0)

  Hysterectomy

28 (4.7)

323 (19.8)

973 (28.7)

1568 (34.2)

1575 (36.3)

1005 (33.8)

269 (26.5)

63 (16.6)

28 (17.7)

  Myomectomy

25 (4.2)

81 (5.0)

142 (4.2)

163 (3.6)

124 (2.9)

57 (1.9)

18 (1.8)

4 (1.1)

4 (2.5)

  Myomectomy and ablation

0 (0.0)

4 (0.2)

9 (0.3)

30 (0.7)

28 (0.6)

15 (0.5)

0 (0.0)

2 (0.5)

0 (0.0)

  Uterine artery embolization

1 (0.2)

9 (0.6)

32 (0.9)

73 (1.6)

80 (1.8)

64 (2.2)

16 (1.6)

1 (0.3)

0 (0.0)

  1. GnRH gonadotropin-releasing hormone, IUD intrauterine device, NSAID non-steroidal anti-inflammatory drug, SD standard deviation, SERM selective estrogen receptor modulator
  2. aTime from index date
  3. bWomen could receive multiple treatments in the 12 months post-index; therefore, individual values may total > 100%
  4. cIncludes IUD/levonorgestrel implants, oral contraceptives, and other contraceptives; hormonal contraceptives were not mutually exclusive and a patient could receive > 1 type